Last updated: February 22, 2026
What is the Current Market Status of NDC 65162-0469?
NDC 65162-0469 is a medication registered under the National Drug Code (NDC) system. It corresponds to Xyrem (sodium oxybate), a central nervous system depressant approved for the treatment of narcolepsy with cataplexy or excessive daytime sleepiness.
The drug is commercially supplied by Jazz Pharmaceuticals, with significant market presence since its approval by the FDA in 2002. The drug’s primary indication limits the market scope to narcolepsy patients, with expanded use in off-label treatments for conditions such as alcohol dependence and fibromyalgia, though these are less prominent.
The medication's market size is driven by the pent-up demand from narcolepsy diagnoses. The worldwide narcolepsy prevalence is estimated at about 0.02% to 0.05%. U.S. narcolepsy cases are estimated at approximately 200,000, with around 50% diagnosed and treated with Xyrem.
Key competitors include Xywav (calcium, magnesium, potassium, and sodium oxybates), a reformulation of Xyrem approved in 2020, which has begun to take market share due to a perceived better safety profile.
Market Drivers and Challenges
Drivers:
- Increasing awareness and diagnosis of narcolepsy.
- Expansion of Xyrem’s approval for additional indications.
- Broader reimbursement coverage from Medicaid and private insurers.
- Ongoing research into off-label uses.
Challenges:
- Strict REMS (Risk Evaluation and Mitigation Strategies) programs constrain distribution.
- Risk of abuse and diversion propels regulatory and logistical hurdles.
- Competition from newer formulations such as Xywav.
- Pricing pressures due to payers' push for cost-effective therapies.
Current Pricing Landscape
Wholesale Acquisition Cost (WAC)
The WAC for Xyrem averages approximately $40,000 to $45,000 per year per patient in the United States. The actual price paid by insurers and patients is often lower due to rebates and negotiated discounts.
Insurance and Reimbursement
Reimbursement coverage varies, with insurance companies necessitating prior authorizations. Out-of-pocket costs for patients depend on their insurance plans, often averaging between $50 and $150 per month with copay assistance programs.
Price Trends
Over the past five years, prices for Xyrem have remained relatively stable, with minor fluctuations linked to rebate adjustments and competitive pressures from Xywav.
Future Price Projections (2023–2028)
| Year |
Projected WAC (USD) |
Rationale |
| 2023 |
$43,000 |
Stable, with slightly increased rebate pressure. |
| 2024 |
$42,500 |
Anticipated rebate-driven discounts intensify. |
| 2025 |
$42,000 |
Competition from Xywav gains market share. |
| 2026 |
$41,500 |
Broader adoption of generic formulations. |
| 2027 |
$41,000 |
Increased generics and biosimilars presence. |
| 2028 |
$40,500 |
Price stabilization, reduced inflationary pressure. |
Note: These projections assume no major regulatory changes or patent litigations that could alter pricing dynamics significantly.
Patent and Regulatory Status
- The original patent for Xyrem expired in 2012, but Jazz Pharmaceuticals holds orphan drug exclusivity and additional patents protecting the formulation until at least 2024.
- The emergence of generic oxybate formulations could drive prices down by approximately 40–50% upon patent expiry.
Competitive Landscape
| Drug Name |
Approval Year |
Formulation |
Market Share (2022) |
Price (USD/year) |
Status |
| Xyrem |
2002 |
Sodium oxybate |
70% |
$43,000 |
Market leader |
| Xywav |
2020 |
Calcium/magnesium oxybate |
20% |
$40,000 |
Growing competitor |
| Generic oxybate |
Expected post-2024 |
Sodium oxybate |
<10% |
TBD |
Entry pending |
Key Market Risks and Opportunities
Risks:
- Regulatory tightening, such as more stringent REMS.
- Patent challenges or patent expirations.
- Advent of alternative therapies (e.g., orexin receptor antagonists).
Opportunities:
- Expanded indications in other sleep-related disorders.
- Geographic expansion in Europe and Asia.
- Development of formulations with reduced abuse potential.
Key Takeaways
- The market for NDC 65162-0469 (Xyrem) remains stable but faces downward price pressure from generic competition and new formulations.
- Pricing in the U.S. averages around $43,000 annually per patient, with potential for slight decreases over the next five years.
- Market growth is driven by increasing diagnoses and expanding off-label uses, despite regulatory and abuse deterrence constraints.
- Patent protections and orphan drug status support pricing power until at least 2024, after which generic entry could significantly reduce prices.
FAQs
1. How is the price of NDC 65162-0469 expected to change over the next five years?
Prices are projected to decline gradually by approximately 5–10% due to increased generic competition and formulary shifts.
2. What factors influence reimbursement rates for this drug?
Reimbursement depends on insurance policies, prior authorization requirements, and patient copayment assistance programs.
3. How might patent expirations impact the market?
Patent expiration around 2024 is likely to lead to generic versions, pressuring brand prices downward by up to 50%.
4. Are there any regulatory risks affecting pricing?
Yes. Tightening REMS and potential off-label restrictions could impact market size and price stability.
5. What are the prospects for expanding the drug’s indications?
Research into off-label uses and new formulations presents opportunities, though regulatory approval is required for new indications.
Sources:
[1] U.S. Food and Drug Administration. (2022). Xyrem (sodium oxybate) approval and label information.
[2] IQVIA. (2022). U.S. Prescription Drug Market Data.
[3] Jazz Pharmaceuticals. (2022). Annual Report and Market Outlook.
[4] Centers for Disease Control and Prevention (CDC). (2022). Narcolepsy prevalence estimates.
[5] Drug Pricing Toolbox. (2023). Wholesale acquisition cost analysis.
